Join the Oncology Voice Network. Join for Free
Best Practices and Creative Ways to Gain KOL Access During COVID-19
Provide 5 SEO Keywords separated by commas

Best Practices and Creative Ways to Gain KOL Access During COVID-19


Share This Article


Summary

In this episode, Tom Caravela speaks with Jason Demuth about his journey from retail pharmacy to the pharmaceutical industry. Jason shares his experiences engaging Key Opinion Leaders (KOLs) during COVID, emphasizing the strategic use of social media and email communication. The discussion explores the future of KOL access and offers strategies for aspiring MSLs. Jason compares roles in big pharma versus small pharma and highlights the importance of networking and recruiters in advancing MSL careers. The episode concludes with Jason's final thoughts and advice, alongside a call for listener engagement.

My guest today is Jason Demuth, Director, Medical Science Liaison at Strongbridge Bio shares creative ways to reach and access KOLs during COVID-19. 

In this episode we discuss:

  • Jason’s background
  • His journey and getting his first MSL role
  • Creative ideas and ways to access KOLs
  • His perspective on LinkedIn and Facebook for KOL engagement
  • Email interaction with KOLs
  • What is the future going to look like in terms of access in Jason’s perspective
  • His advice for new MSLs or those breaking into the role
  • Jason’s  advice for MSLs and/or MSL Leaders as we look to the future

Click for Source
Provide 5 SEO Keywords separated by commas

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Article
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
OVN Avatar B. Gyawali, E. G. E. de Vries, U. Dafni, T. Amaral, J. Barriuso, J. Bogaerts, A. Calles, G. Curigliano, C. Gomez-Roca, B. Kiesewetter, S. Oosting, A. Passaro, G. Pentheroudakis, M. Piccart, F. Roitberg, J. Tabernero, N. Tarazona, D. Trapani, R. Wester, G.

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring

Explore OVN